Development of Effective Therapeutics Targeting HER3 for Cancer Treatment

Table 1 Mono- and bi-specific anti-HER3 Abs under clinical studies in cancer patients

Abs	Target	Most advanced clinical phase	Clinicaltrials.gov identifier	Current Results on clinicaltrials.gov	Sponsor
mAbs:
U3–1287/Patritumab	HER3	Phase III	NCT02134015	Terminated (Pre-defined criteria Not reached)	Daiichi Sankyo
MM-121/Seribantumab	HER3	Phase II	NCT00994123	MM-121+ erlotinib ineffective to prolong PFS in EGFR WT NSCLC	Merrimack Pharmaceuticals
RG7116/Lumretuzumab	HER3	Phase I	NCT01482377	No results posted	Roche
LJM716/Elgemtumab	HER3	Phase I/II	NCT01822613	No results posted	Novartis
U3–1402	HER3	Phase I/II	NCT02980341	Ongoing	Daiichi Sankyo
AV-203	HER3	Phase I	NCT01603979	No results posted	Aveo Oncologyo
KTN3379/CDX-3379	HER3	Phase I	NCT02014909	No results posted	Celldex Therapeutics
GSK2849330	HER3	Phase I	NCT01966445	Results submitted, But not posted	GlaxoSmithKline
Bispecific Abs:
MM-111	HER2/HER3	Phase II	NCT01774851	Terminated (Lack of efficacy)	Merrimack Pharmaceuticals
MCLA-128	HER2/HER3	Phase II	NCT03321981	Ongoing	Merus NV
MM-141/Istiratumab	HER3/IGF-1R	Phase II	NCT02399137	No results posted	Merrimack Pharmaceuticals
MEHD7945A/Duligotumab	HER3/EGFR	Phase II	NCT01652482	No results posted	Genentech

ISSN: 1480-9222